Overview

This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.

Eligibility

Inclusion Criteria:

• Patients with a histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) who plan to receive treatment at the Moffitt Cancer Center will be eligible.
• Must have ability to comprehend and the willingness to sign written informed consent for study participation.
• Eligible to receive CAR T-cell therapy (axicabtagene ciloleucel) for LBCL and histological variants approved by the standard of care label
• ECOG performance status 0 to 2.
• At least one high-risk lesion, defined as measuring ≥ 5 cm, that is targetable for radiotherapy per investigator assessment.
• Ability to undergo comprehensive bridging radiation, defined as radiation to all visible sites of disease.
• No evidence or suspicion of active central nervous system (CNS) involvement of lymphoma
• Adequate bone marrow and organ function as defined in protocol.

        The effects of therapeutic agents used in this trial on developing human fetus are unknown,
        and because of this, women of child-bearing potential and men must agree to use adequate
        contraception (hormonal or barrier method of birth control; abstinence) prior to study
        entry and for the duration of study participation as outlined in criteria below:
          -  Men must agree to take appropriate precautions to avoid fathering children (with at
             least 99% certainty) from screening through safety follow up and must refrain from
             donating sperm during this period. Permitted methods that are at least 99% effective
             in preventing pregnancy should be communicated to the participants in their
             understanding confirmed.
          -  Women of childbearing potential must have a negative serum or urine pregnancy test at
             screening and at time of radiation treatment planning, per standard of care and
             departmental standard operating procedure. Patients must agree to take appropriate
             precautions to avoid pregnancy (with at least 99% certainty) from screening through
             safety follow up. Permitted methods that are at least 99% effective in preventing
             pregnancy should be communicated to the participants and their understanding
             confirmed.
          -  Women of non-childbearing potential (i.e., surgically sterile with a hysterectomy
             and/or bilateral oophorectomy OR ≥12 months of amenorrhea) are eligible.
        Exclusion Criteria:
          -  Patients who are currently receiving or who have received any other investigational
             study agent ≤4 weeks prior to screening visit are ineligible
          -  Prior treatment with chimeric antigen receptor (CAR) T-cell therapy
          -  Inability to safely deliver comprehensive radiation therapy to all sites of disease
             per treating radiation oncologists' discretion
          -  Participants with clinically significant or uncontrolled cardiac disease, including
             unstable angina, acute myocardial infarction within 6 months from screening, New York
             Health Association III or IV heart failure, and circulatory collapse requiring
             vasopressor or inotropic support.
          -  Participants with arrhythmias that are not stable on a medical management program
             within 2 weeks of screening are also excluded.
          -  Evidence of active uncontrolled/untreated infection (viral, bacterial, fungal,
             opportunistic) of any origin.
          -  Known positive Human immunodeficiency virus (HIV) status.
          -  Participants with evidence of active and/or chronic hepatitis B virus (HBV) infection,
             HBV viral load must be undetectable on suppressive therapy, if indicated.
          -  Participants with a history of hepatitis C virus (HCV) infection, HCV must have a
             negative nucleic acid test post-treatment or spontaneous clearance.
          -  Participants who require the concurrent use of chronic systemic steroids or
             immunosuppressant medications. Steroids should not be given within 5 days prior to
             leukapheresis. Concomitant bridging steroids (Section 6.6) are allowed after
             leukapheresis.
          -  Any condition that would, in the investigator's judgement, interfere with full
             participation in the study and attending required study visits (if outpatient); pose a
             significant risk to the participant; or interfere with interpretation of study data.
          -  In the investigator's judgment, the subject is unlikely to complete all
             protocol-required study visits or procedures, including follow-up visits, or comply
             with the study requirements for participation including ability to safely undergo
             radiation treatment planning and delivery.
          -  Women of childbearing potential who are pregnant or breastfeeding. Females who have
             undergone surgical sterilization or who have been postmenopausal for at least 12
             months are not considered to be of childbearing potential.